UK medtech innovator QV Bioelectronics raises £4.5 million to advance…

Team S · 2026-01-26T14:12:22.000Z

QV Bioelectronics, a Cheshire, United Kingdom-based medtech startup, has secured £4.5 million in funding and grants to advance its pioneering implantable device for glioblastoma (GBM) treatment into first-in-human clinical studies and bring the technology closer to clinical use. The company’s flagship product, GRACE (Glioma Resection Advanced Cavity Electric Field therapy), is a novel electric field therapy implant designed to kill residual brain cancer cells following surgical resection a condition where current treatment options are limited and survival rates are low. The fresh capital will help QV Bioelectronics accelerate clinical trial preparation, strengthen research and development, and expand its team as it works toward potentially transforming outcomes for thousands of patients affected by this aggressive form of brain cancer. This funding round was led by PXN Ventures, investing via the GMC Life Sciences Fund, and supported by NPIF II - PXN Equity Finance, Empirical Ventures, and a syndicate of angel investors- alongside non-dilutive funding from the National Institute for Health and Care Research and Innovate UK. The backing from both venture and grant sources demonstrates confidence in QV’s patented electric field therapy approach and its potential to redefine treatment standards in neuro-oncology. The company plans to use the capital to continue lab validation and drive its first-in-human clinical study slated for 2026.

Member Login Get Access

UK medtech innovator QV Bioelectronics raises £4.5 million to advance… | Newnex